Actively Recruiting
Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
Led by Weill Medical College of Cornell University · Updated on 2026-02-27
20
Participants Needed
1
Research Sites
120 weeks
Total Duration
On this page
Sponsors
W
Weill Medical College of Cornell University
Lead Sponsor
C
Curium US LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study team hypothesizes that it is feasible to intraoperatively detect tumor following \[CU64\]DOTATATE injection using the gamma probe device.
CONDITIONS
Official Title
Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
Who Can Participate
Eligibility Criteria
You may qualify if you...
- High suspicion of meningioma requiring surgical removal based on MRI, or diagnosis of meningioma from prior surgery with suspected recurrent or residual tumor needing repeat surgery
You will not qualify if you...
- Pregnant or breastfeeding
- Undergoing surgical procedures where the gamma probe cannot be used (such as endoscopic endonasal or eyebrow incision surgeries)
- Allergy to somatostatin analogs
- Contraindications to standard MRI
- History of cranial radiation therapy
- Currently enrolled in other meningioma treatment clinical trials
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
New York-Presbyterian/Weill Cornell Medical Center
New York, New York, United States, 10021
Actively Recruiting
Research Team
J
Jana Ivanidze, MD/PhD
CONTACT
A
Alexis Watson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here